Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029

Pages: 148 Published: December 29, 2022 Report Code: GDHC260PIDR

Type 2 Diabetes (T2D) Market Report Overview

The T2D market value for the 9 markets (9MM) was $45.9 billion in 2019. T2D is a chronic disease characterized by insulin resistance and pancreatic β-cell failure, as defined by the International Classification of Diseases 11th edition (ICD-11), with an underlying genetic predisposition heavily influenced by diet and lifestyle. This disease is a multi-causal, heterogeneous, and progressive cardiometabolic condition that is commonly associated with obesity, dyslipidemia, hypertension, inflammation, and endothelial dysfunction. The prevalence of diabetes is expected to grow rapidly, as it is associated with aging populations, increasing urbanization, economic development, and the increase in the prevalence of risk factors like obesity, unhealthy dietary habits, and physical inactivity.

The T2D market research report provides an analysis of the key dynamics of the T2D market. The report also offers insights into the key industry drivers and challenges. It also covers deals and R&D strategies in detail to highlight potential business opportunities.

T2D Market Drivers

The most important driver of growth in the T2D marketplace will be a dramatic increase in the prevalence and diagnosis of the disease. The rise in T2D-related comorbidities has fueled the more aggressive approach to the treatment and the use of multiple-drug therapies.

The obesity epidemic in the US will fuel the number of T2D patients. The main shift in the position of the ADA guidelines, reflected in a more personalized and patient-tailored approach, will drive the market for many me-too therapies in the T2D space. Diabetes screening programs for high-risk patients could increase the patient pool. Increasing rates of obesity and heart disease lead to a likely increase in the incidence of Type 2 Diabetes, further driven by the ageing population in the EU.

To know more about the drivers of the T2D market, download a free report sample

T2D Market Unmet Needs

Several newly marketed and late-stage pipeline products are positioned to somewhat address the unmet needs in the treatment of T2D.  New insulin formulations are also emerging, but they only offer a modest increase in overall efficacy and safety. Overall, the majority of unmet needs in T2D will remain unfulfilled for the foreseeable future. Patients still lack an effective antidiabetic treatment that can be used in all phases of the chronic disease, leaving a significant growth opportunity for new patented products that can meet these needs.

To know more about the unmet needs in the T2D market, download a free report sample

T2D Market Segmentation by Regions

The key regions in the T2D market are the US, 5EU (France, Germany, Italy, Spain, and the UK), and APAC (China, India, and Japan). The US had the highest share in 2019, followed by APAC, and 5EU respectively.

T2D Market Analysis by Regions

T2D Market Analysis by RegionsFor more regional insights on the T2D market, download a free report sample

T2D Market - Competitive Landscape

Some of the leading players in the T2D market are Takeda, GSK, AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly, Merck, and others. Takeda is the leading sponsor of cell therapy trials in T2D.

T2D Market Analysis by CompaniesT2D Market Analysis by CompaniesFor more insights on companies in the T2D market, download a free report sample

T2D Market Report Overview

Market Size (2019 in 9MM) $45.9 billion
Key Regions The US, 5EU (France, Germany, Italy, Spain, and the UK), and APAC (China, India, and Japan)
Leading Players Takeda, GSK, AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly, Merck, and others

Scope

  • The proportion of people at risk of developing T2D is expected to increase over the 10-year forecast period due to an increased life expectancy coupled with rapid socioeconomic change, increased prevalence of obesity and the increased prevalence of cardiovascular (CV) disease
  • The potential launch of 10 late-stage pipeline agents will increase the number of patients who can be offered pharmacological treatment options. In addition, five of these drugs in late-stage development are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
  • Cardiorenal disease is being increasingly recognized in clinical practice and there has been a renewed interest among the medical community to understand the pathophysiological mechanisms underpinning its pathogenesis.
  • Despite the plethora of therapies currently available to T2D patients, there is still room for improvement within the treatment space. The most recognizable is the need for novel treatment options for patients unable to achieve optimal glycemic control.

Reasons to Buy

The report will help to understand:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global type 2 diabetes market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global type 2 diabetes therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

Eli Lilly
Novo Nordisk
Sanofi
AstraZeneca
Merck & Co.
Boehringer Ingelheim
GlaxoSmithKline
Takeda
Roche
Pfizer
Johnson & Johnson
Novartis
Theracos
Lexicon Pharmaceuticals
Hua Medicine Shanghai Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd.
Sihuan Pharmaceutical Holdings Group
Biocon Ltd
Oramed Pharamceuticals

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Type 2 Diabetes (T2D): Executive Summary – Updated Dec 2022, based on events up to Dec 5, 2022

1.1 Continued, Significant Growth in the T2D Market, With Drug Sales Expected to Almost Double Across the 9MM by the End of the Forecast Period

1.2 T2D Developers Battle for Share in an Increasingly Crowded Market

1.3 Decrease in Sales Among Branded T2D Drugs Across the 9MM

1.4 Glucagon-Like Peptide -1 Receptor Agonist Class Faces Intense Internal Competition, Largely Revolving Around Drugs’ Ability to Improve Patient Compliance/Ease of Administration and Reduced Risk of Major Adverse Cardiovascular Events

1.5 Label Expansions for SGLT-2 Inhibitors

1.6 What Do Physicians Think?

2 Introduction – Updated Dec 2022, based on events up to Dec 5, 2022

2.1 Catalyst

2.2 Related Reports

3 Disease Overview

3.1 Etiology

3.2 Pathophysiology

3.3 Symptoms

3.4 Prognosis and Quality of Life

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of T2D

4.4.3 Forecast Assumptions and Methods: Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D

4.4.4 Forecast Assumptions and Methods: Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D

4.4.5 Forecast Assumptions and Methods: Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D

4.4.6 Forecast Assumptions and Methods: Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D

4.4.7 Forecast Assumptions and Methods: Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D

4.4.8 Forecast Assumptions and Methods: Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D

4.5 Epidemiological Forecast for Type 2 Diabetes (2018–2028)

4.5.1 Diagnosed Prevalent Cases of T2D

4.5.2 Age-Specific Diagnosed Prevalent Cases of T2D

4.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D

4.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 Limitations of the Analysis

4.6.3 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 US

5.3 5EU

5.3.1 France

5.3.2 Germany

5.3.3 Italy

5.3.4 Spain

5.3.5 UK

5.4 Japan

5.5 China

5.6 India

6 Competitive Assessment – Updated Dec 2022, based on events up to Dec 5, 2022

6.1 Overview

7 Unmet Needs and Opportunities

7.1 Overview

7.2 Disease-Modifying Treatments Providing Sustained Glycemic Control

7.3 Drugs with Non-glycemic Benefits

7.4 Drugs with Improved Side-Effect Profiles

7.5 Increased Patient Compliance

7.6 Drugs for the Emergent T2D Pediatric Population

7.7 Controls on Insulin Drug Pricing and the Need for Fairly Priced Biologics

8 Pipeline Assessment – Updated Dec 2022, based on events up to Dec 5, 2022

8.1 Overview

8.2 Promising Drugs in Clinical Development

9 Current and Future Players – Updated Dec 2022, based on events up to Dec 5, 2022

9.1 Overview

9.2 Trends in Corporate Strategy

10 Market Outlook – Updated Dec 2022, based on events up to Dec 5, 2022

10.1 Global Markets

10.1.1 Forecast

10.1.2 Drivers and Barriers – Global Issues

10.2 US

10.2.1 Forecast

10.2.2 Key Events

10.2.3 Drivers and Barriers

10.3 5EU

10.3.1 Forecast

10.3.2 Key Events

10.3.3 Drivers and Barriers

10.4 Japan

10.4.1 Forecast

10.4.2 Key Events

10.4.3 Drivers and Barriers

10.5 China

10.5.1 Forecast

10.5.2 Key Events

10.5.3 Drivers and Barriers

10.6 India

10.6.1 Forecast

10.6.2 Key Events

10.6.3 Drivers and Barriers

11 Appendix

11.1 Abbreviations

11.2 Bibliography

11.3 Methodology

11.3.1 Forecasting Methodology

11.4 Physicians and Specialists Included in this Study

11.5 About the Authors

11.5.1 Healthcare Analyst

11.5.2 Therapy Area Director

11.5.3 Epidemiologists

11.5.4 Vice President of Disease Analysis and Intelligence

11.5.5 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: T2D: Key Metrics in the Nine Major Pharmaceutical Markets

Table 2: Primary Pathophysiologic Conditions Associated with T2D

Table 3: Symptoms of T2D presents an overview of the most frequently observed symptoms for T2D.

Table 4: Risk Factors and Comorbidities for T2D

Table 5: Diagnostic Tests and Typical Criteria for Diagnosing T2D

Table 6: Country Profile, T2D Management, US

Table 7: Country Profile, T2D Management, France

Table 8: Country Profile, T2D Management, Germany

Table 9: Absence of Typical T2D Symptoms, Italy

Table 10: Individuals with Increased Risk of T2D, Italy

Table 11: Country Profile, T2D Management, Italy

Table 12: Country Profile, T2D Management, Spain

Table 13: Country Profile, T2D Management, UK

Table 14: Country Profile, T2D Management, Japan

Table 15: Country Profile, T2D Management, China

Table 16: Country Profile, T2D Management, India

Table 17: Leading Branded Treatments for T2D, 2022

Table 18: T2D Market – Drivers and Barriers, 2020

Table 19: Key Events Impacting Sales for T2D in the US, 2019–2029

Table 20: T2D Market – Drivers and Barriers in the US, 2020

Table 21: Key Events Impacting Sales for T2D in the 5EU, 2019–2029

Table 22: T2D Market – Drivers and Barriers in the 5EU, 2020

Table 23: Key Events Impacting Sales for T2D in Japan, 2019–2029

Table 24: T2D Market – Drivers and Barriers in Japan, 2020

Table 25: Key Events Impacting Sales for T2D in China, 2019–2029

Table 26: T2D Market – Drivers and Barriers in China, 2020

Table 27: Key Events Impacting Sales for T2D in India, 2019–2029

Table 28: T2D Market – Drivers and Barriers in India, 2020

Table 29: Number of High-Prescribing Physicians Surveyed

List of Figures

Figure 1: Global Sales By Region (Type 2 Diabetes) 2019 and 2029

Figure 2: Company Portfolio Gap Analysis in T2D, 2019–2029

Figure 3: Competitive Assessment of Late-Stage (Phase III) Pipeline Agents in T2D, 2019–2029

Figure 4: T2D Pathophysiology

Figure 5: 9MM, Diagnosed Prevalence of T2D (%), Men, All Ages, 2018

Figure 6: 9MM, Diagnosed Prevalence of T2D (%), Women, All Ages, 2018

Figure 7: 9MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of T2D

Figure 8: 9MM, Sources Used to Forecast the Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D

Figure 9: 9MM, Sources Used to Forecast the Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D

Figure 10: 9MM, Sources Used to Forecast the Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D

Figure 11: 9MM, Sources Used to Forecast the Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D

Figure 12: 9MM, Sources Used to Forecast the Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D

Figure 13: 9MM, Sources Used to Forecast the Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D

Figure 14: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 15: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N, 2018

Figure 16: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, All Ages, N, 2018

Figure 17: 9MM, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 18: 9MM, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 19: 9MM, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 20: 9MM, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 21: 9MM, Diagnosed Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 22: 9MM, Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 23: ADA Treatment Algorithm for Antihyperglycemic Therapy in T2D

Figure 24: Unmet Needs and Opportunities in T2D

Figure 25: Pipeline Agents in Development for T2D

Figure 26: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to be Licensed for T2D in the 9MM During the Forecast Period

Figure 27: Company Portfolio Gap Analysis in T2D, 2019–2029

Figure 28: Global Sales for T2D by Country/Region, 2019 and 2029

Figure 29: Sales for T2D in the US by Drug Class, 2019 and 2029

Figure 30: Sales for T2D in the 5EU by Drug Class, 2019 and 2029

Figure 31: Sales for T2D in Japan by Drug Class, 2019 and 2029

Figure 32: Sales for T2D in China by Drug Class, 2019 and 2029

Figure 33: Sales for T2D in India by Drug Class, 2019 and 2029

Frequently Asked Questions

The T2D market value for the 9MM was $45.9 billion in 2019.Some of the leading players in the T2D market are Takeda, GSK, AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly, Merck, and others.

The key regions in the T2D market are the US, 5EU (France, Germany, Italy, Spain, and the UK), and APAC (China, India, and Japan).

The US has the highest share in the T2D market.

Some of the leading players in the T2D market are Takeda, GSK, AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly, Merck, and others.

$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Enquire Before Buying

Request a Free Sample

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods